Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | SpringerLink
PCYC 2014.12.31 - 10-K
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect
ABBVIE: IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint | American Pharmacy News
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect
Progression-free survival and overall survival for ibrutinib and... | Download Scientific Diagram
Cancers | Free Full-Text | Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
iLLUMINATE - Progression-Free Survival | IMBRUVICA® (ibrutinib) HCP
iLLUMINATE - Progression-Free Survival | IMBRUVICA® (ibrutinib) HCP
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials - Allan - 2022 - British Journal of Haematology -
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
Frontiers | Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | SpringerLink
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials - Allan - 2022 - British Journal of Haematology -
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology
Folie 1
IMBRUVICA® IN chronic lymphocytic leukaemia (CLL): experience you can rely on<sup>1-5</sup>
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
